Document is current
Any future updates will be listed below
-
Authors
Won, Ki-Bum
Lee, Byoung Kwon
Park, Hyung-Bok
Heo, Ran
Lee, Sang-Eun
Rizvi, Asim
Lin, Fay Y.
Kumar, Amit
Hadamitzky, Martin
Kim, Yong-Jin
Sung, Ji Min
Conte, Edoardo
Andreini, Daniele
Pontone, Gianluca
Budoff, Matthew J.
Gottlieb, Ilan
Chun, Eun Ju
Cademartiri, Filippo
Maffei, Erica
Marques, Hugo
de Araújo Gonçalves, Pedro
Leipsic, Jonathon A.
Shin, Sanghoon
Choi, Jung Hyun
Virmani, Renu
Samady, Habib
Chinnaiyan, Kavitha
Raff, Gilbert L.
Stone, Peter H.
Berman, Daniel S.
Narula, Jagat
Shaw, Leslee J.
Bax, Jeroen J.
Min, James K.
Chang, Hyuk-Jae http://orcid.org/0000-0002-6139-7545
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02803411 at ClinicalTrials.govDocuments that mention this clinical trial
Coronary artery calcium paradox and physical activity
https://doi.org/10.1136/heartjnl-2021-319868
Quantitative assessment of coronary plaque volume change related to triglyceride glucose index: The Progression of AtheRosclerotic PlAque DetermIned by Computed TomoGraphic Angiography IMaging (PARADIGM) registry
https://doi.org/10.1186/s12933-020-01081-w
Rapid Plaque Progression Is Independently Associated With Hyperglycemia and Low HDL Cholesterol in Patients With Stable Coronary Artery Disease: A PARADIGM Study
https://doi.org/10.1161/circimaging.123.016481
-
Funding
Funding for this research was provided by:
National Research Foundation of Korea (2012027176)
- License Information
-
More Information
Article History
Received: 24 April 2020
Accepted: 2 July 2020
First Online: 18 July 2020
Ethics approval and consent to participate
: The study protocol was approved by ethics committee of each institution, and informed consent for the procedure was obtained from each participant.
: Not applicable.
: Dr. James K. Min receives funding from the Dalio Foundation, National Institutes of Health, and GE Healthcare. Dr. Min serves on the scientific advisory board of Arineta and GE Healthcare, and has a clear equity interest. Dr. Habib Samaday has equity interest in Covanos. All other authors declared no conflict of interest.
